Market Cap | 483.53M | P/E | 46.62 | EPS this Y | -51.10% | Ern Qtrly Grth | - |
Income | -112.64M | Forward P/E | -2.55 | EPS next Y | -30.00% | 50D Avg Chg | -5.00% |
Sales | 12.6M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -20.00% |
Dividend | N/A | Price/Book | 0.74 | EPS next 5Y | - | 52W High Chg | -51.00% |
Recommedations | 1.60 | Quick Ratio | 13.46 | Shares Outstanding | 35.84M | 52W Low Chg | 8.00% |
Insider Own | 0.54% | ROA | -12.97% | Shares Float | 24.79M | Beta | 1.15 |
Inst Own | 102.36% | ROE | -18.19% | Shares Shorted/Prior | 1.80M/1.73M | Price | 13.52 |
Gross Margin | 100.00% | Profit Margin | - | Avg. Volume | 284,985 | Target Price | 36.25 |
Oper. Margin | -1,171.69% | Earnings Date | May 8 | Volume | 250,232 | Change | -2.10% |
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
JP Morgan | Overweight | Mar 12, 24 |
HC Wainwright & Co. | Buy | Mar 7, 24 |
JP Morgan | Overweight | Nov 13, 23 |
Wedbush | Outperform | Oct 18, 23 |
HC Wainwright & Co. | Buy | Aug 9, 23 |
HC Wainwright & Co. | Buy | Mar 17, 23 |
JP Morgan | Overweight | Mar 16, 23 |
Wedbush | Outperform | Mar 16, 23 |
SVB Leerink | Outperform | May 13, 22 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Gall Matthew | Chief Financial Offi.. Chief Financial Officer | Oct 12 | Buy | 8.37 | 5,000 | 41,850 | 19,429 | 10/12/23 |
Boxer Capital, LLC | Other Other | Aug 23 | Sell | 15.56 | 350,000 | 5,446,000 | 1,804,058 | 08/25/23 |
Call Matthew | Chief Operating Offi.. Chief Operating Officer | Mar 28 | Option | 2.95 | 40,226 | 118,667 | 93,898 | 03/29/23 |
Hallal David | Director Director | Jun 08 | Option | 3.91 | 29,615 | 115,795 | 1,171 | 06/10/22 |
Hallal David | Director Director | Jun 08 | Sell | 20.04 | 29,615 | 593,485 | 06/10/22 | |
Davis Aaron I. | Director Director | May 09 | Sell | 22.02 | 663,000 | 14,599,260 | 2,154,058 | 05/11/22 |
Davis Aaron I. | Director Director | Apr 28 | Sell | 27.41 | 375,000 | 10,278,750 | 2,817,058 | 05/02/22 |
Detheux Michel | Chief Executive Offi.. Chief Executive Officer | Apr 18 | Option | 4.23 | 11,500 | 48,645 | 37,763 | 04/19/22 |
Detheux Michel | Chief Executive Offi.. Chief Executive Officer | Apr 18 | Sell | 32.26 | 11,500 | 370,990 | 26,263 | 04/19/22 |
Davis Aaron I. | Director Director | Mar 22 | Buy | 32.81 | 50,000 | 1,640,500 | 3,192,058 | 03/24/22 |
Detheux Michel | Chief Executive Offi.. Chief Executive Officer | Mar 21 | Sell | 34.82 | 18,437 | 641,976 | 26,263 | 03/22/22 |
Boxer Capital, LLC | 10% Owner 10% Owner | Mar 17 | Sell | 35.25 | 575,201 | 20,275,835 | 3,142,058 | 03/18/22 |
Lager Joanne Jenkins | Chief Medical Office.. Chief Medical Officer | Mar 11 | Option | 4.3 | 3,500 | 15,050 | 3,500 | 03/14/22 |
Lager Joanne Jenkins | Chief Medical Office.. Chief Medical Officer | Mar 11 | Sell | 36.01 | 3,500 | 126,035 | 03/14/22 | |
McGrath Yvonne | Chief Scientific Off.. Chief Scientific Officer | Mar 01 | Option | 4.24 | 10,000 | 42,400 | 10,000 | 03/02/22 |
McGrath Yvonne | Chief Scientific Off.. Chief Scientific Officer | Mar 01 | Sell | 36.76 | 10,000 | 367,600 | 03/02/22 | |
Detheux Michel | Chief Executive Offi.. Chief Executive Officer | Feb 23 | Sell | 34.81 | 14,500 | 504,745 | 34,700 | 02/24/22 |
Lager Joanne Jenkins | Chief Medical Office.. Chief Medical Officer | Feb 11 | Option | 4.3 | 3,500 | 15,050 | 3,500 | 02/14/22 |
Lager Joanne Jenkins | Chief Medical Office.. Chief Medical Officer | Feb 11 | Sell | 35.9 | 3,500 | 125,650 | 02/14/22 | |
Detheux Michel | Chief Executive Offi.. Chief Executive Officer | Jan 25 | Sell | 35.83 | 14,500 | 519,535 | 49,200 | 01/26/22 |
Lager Joanne Jenkins | Chief Medical Office.. Chief Medical Officer | Jan 14 | Option | 4.3 | 3,500 | 15,050 | 3,500 | 01/18/22 |
Lager Joanne Jenkins | Chief Medical Office.. Chief Medical Officer | Jan 14 | Sell | 39.42 | 3,500 | 137,970 | 01/18/22 | |
Boxer Capital, LLC | Director Director | Jan 03 | Sell | 46.11 | 700,000 | 32,277,000 | 01/05/22 | |
Lager Joanne Jenkins | Chief Medical Office.. Chief Medical Officer | Jan 03 | Option | 4.3 | 7,000 | 30,100 | 7,000 | 01/04/22 |
Lager Joanne Jenkins | Chief Medical Office.. Chief Medical Officer | Jan 03 | Sell | 51.9 | 7,000 | 363,300 | 01/04/22 | |
Detheux Michel | Chief Executive Offi.. Chief Executive Officer | Dec 02 | Option | 4.3 | 30,000 | 129,000 | 79,863 | 12/22/21 |
Detheux Michel | Chief Executive Offi.. Chief Executive Officer | Dec 02 | Sell | 44.62 | 44,500 | 1,985,590 | 63,700 | 12/22/21 |
Hallal David | Director Director | Dec 20 | Option | 3.63 | 50,000 | 181,500 | 50,000 | 12/22/21 |
Hallal David | Director Director | Dec 20 | Sell | 43.57 | 50,000 | 2,178,500 | 12/22/21 | |
Lager Joanne Jenkins | Chief Medical Office.. Chief Medical Officer | Dec 17 | Option | 4.3 | 7,000 | 30,100 | 7,000 | 12/17/21 |
Lager Joanne Jenkins | Chief Medical Office.. Chief Medical Officer | Dec 17 | Sell | 41 | 7,000 | 287,000 | 12/17/21 | |
Lager Joanne Jenkins | Chief Medical Office.. Chief Medical Officer | Dec 10 | Option | 4.3 | 3,500 | 15,050 | 3,500 | 12/10/21 |
Lager Joanne Jenkins | Chief Medical Office.. Chief Medical Officer | Dec 10 | Sell | 34.5 | 3,500 | 120,750 | 12/10/21 | |
MPM BIOVENTURES 2018, L.P. | 10% Owner 10% Owner | Dec 03 | Sell | 34.3 | 49,831 | 1,709,203 | 2,885,470 | 12/07/21 |
MPM BioVentures 2014, L.P. | 10% Owner 10% Owner | Dec 03 | Sell | 34.3 | 49,831 | 1,709,203 | 2,885,470 | 12/07/21 |
GADICKE ANSBERT | 10% Owner 10% Owner | Dec 03 | Sell | 34.3 | 83,390 | 2,860,277 | 4,730,197 | 12/07/21 |
MPM BIOVENTURES 2018, L.P. | 10% Owner 10% Owner | Nov 30 | Sell | 34.59 | 83,519 | 2,888,922 | 2,935,301 | 12/02/21 |
MPM BioVentures 2014, L.P. | 10% Owner 10% Owner | Nov 30 | Sell | 34.59 | 83,519 | 2,888,922 | 2,935,301 | 12/02/21 |
GADICKE ANSBERT | 10% Owner 10% Owner | Nov 30 | Sell | 34.59 | 139,773 | 4,834,748 | 4,813,587 | 12/02/21 |
MPM BIOVENTURES 2018, L.P. | 10% Owner 10% Owner | Nov 26 | Sell | 35.34 | 23,045 | 814,410 | 3,018,820 | 11/30/21 |
MPM BioVentures 2014, L.P. | 10% Owner 10% Owner | Nov 26 | Sell | 35.34 | 23,045 | 814,410 | 3,018,820 | 11/30/21 |
GADICKE ANSBERT | 10% Owner 10% Owner | Nov 26 | Sell | 35.34 | 38,566 | 1,362,922 | 4,953,360 | 11/30/21 |
Detheux Michel | Chief Executive Offi.. Chief Executive Officer | Nov 22 | Option | 12.45 | 16,263 | 202,474 | 92,700 | 11/24/21 |
Detheux Michel | Chief Executive Offi.. Chief Executive Officer | Nov 22 | Sell | 36.08 | 14,500 | 523,160 | 78,200 | 11/24/21 |
GADICKE ANSBERT | 10% Owner 10% Owner | Nov 17 | Sell | 36.56 | 129,617 | 4,738,798 | 4,991,926 | 11/24/21 |
MPM BIOVENTURES 2018, L.P. | 10% Owner 10% Owner | Nov 17 | Sell | 36.56 | 77,455 | 2,831,755 | 3,041,865 | 11/24/21 |
Lager Joanne Jenkins | Chief Medical Office.. Chief Medical Officer | Nov 18 | Option | 4.3 | 28,000 | 120,400 | 28,000 | 11/19/21 |
Lager Joanne Jenkins | Chief Medical Office.. Chief Medical Officer | Nov 18 | Sell | 34.5 | 28,000 | 966,000 | 11/19/21 | |
Detheux Michel | Chief Executive Offi.. Chief Executive Officer | Oct 15 | Sell | 28.01 | 1,836 | 51,426 | 97,190 | 10/19/21 |
MPM BIOVENTURES 2018, L.P. | 10% Owner 10% Owner | Oct 15 | Sell | 27.56 | 17,099 | 471,248 | 3,134,991 | 10/18/21 |